230 related articles for article (PubMed ID: 34370413)
1. [Controversies in neurology: Diagnosis, follow up and therapy of multiple sclerosis with pathomechanismal approach].
Vécsei L
Ideggyogy Sz; 2021 Jul; 74(7-08):249-255. PubMed ID: 34370413
[TBL] [Abstract][Full Text] [Related]
2. Natural history of multiple sclerosis: a unifying concept.
Confavreux C; Vukusic S
Brain; 2006 Mar; 129(Pt 3):606-16. PubMed ID: 16415308
[TBL] [Abstract][Full Text] [Related]
3. [Current questions of multiple sclerosis: the secunder progressive form of the disease].
Vécsei L
Ideggyogy Sz; 2020 Jan; 73(1-2):7-14. PubMed ID: 32057199
[TBL] [Abstract][Full Text] [Related]
4. Approaches and challenges in the diagnosis and management of secondary progressive multiple sclerosis: A Central Eastern European perspective from healthcare professionals.
Boyko A; Therapontos C; Horakova D; Szilasiová J; Kalniņa J; Kolontareva J; Gross-Paju K; Selmaj K; Sereike I; Milo R; Gabelić T; Rot U
Mult Scler Relat Disord; 2021 May; 50():102778. PubMed ID: 33592384
[TBL] [Abstract][Full Text] [Related]
5. The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability.
Scalfari A; Neuhaus A; Degenhardt A; Rice GP; Muraro PA; Daumer M; Ebers GC
Brain; 2010 Jul; 133(Pt 7):1914-29. PubMed ID: 20534650
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic uncertainty during the transition to secondary progressive multiple sclerosis.
Katz Sand I; Krieger S; Farrell C; Miller AE
Mult Scler; 2014 Oct; 20(12):1654-7. PubMed ID: 24493475
[TBL] [Abstract][Full Text] [Related]
7. The apparently milder course of multiple sclerosis: changes in the diagnostic criteria, therapy and natural history.
Sorensen PS; Sellebjerg F; Hartung HP; Montalban X; Comi G; Tintoré M
Brain; 2020 Sep; 143(9):2637-2652. PubMed ID: 32710096
[TBL] [Abstract][Full Text] [Related]
8. [Clinical evaluation of follow-up and disease course].
Roullet E
Rev Neurol (Paris); 2001 Sep; 157(8-9 Pt 2):1121-3. PubMed ID: 11787343
[TBL] [Abstract][Full Text] [Related]
9. Results from SPECTRUM: A survey of healthcare professionals to understand current diagnosis and management practices for secondary progressive multiple sclerosis in the United Kingdom.
Duddy M; Wilkinson C; Medhurst S; Rhys K
Mult Scler Relat Disord; 2021 Oct; 55():103174. PubMed ID: 34399317
[TBL] [Abstract][Full Text] [Related]
10. Recent Progress in the Identification of Early Transition Biomarkers from Relapsing-Remitting to Progressive Multiple Sclerosis.
Maier S; Barcutean L; Andone S; Manu D; Sarmasan E; Bajko Z; Balasa R
Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36901807
[TBL] [Abstract][Full Text] [Related]
11. [Immunomodulatory therapy in multiple sclerosis].
Csépány T; Bereczki D
Ideggyogy Sz; 2004 Nov; 57(11-12):401-16. PubMed ID: 15662768
[TBL] [Abstract][Full Text] [Related]
12. Brain atrophy in relapsing-remitting multiple sclerosis and secondary progressive multiple sclerosis: longitudinal quantitative analysis.
Ge Y; Grossman RI; Udupa JK; Wei L; Mannon LJ; Polansky M; Kolson DL
Radiology; 2000 Mar; 214(3):665-70. PubMed ID: 10715027
[TBL] [Abstract][Full Text] [Related]
13. Predicting cognitive decline in multiple sclerosis: a 5-year follow-up study.
Eijlers AJC; van Geest Q; Dekker I; Steenwijk MD; Meijer KA; Hulst HE; Barkhof F; Uitdehaag BMJ; Schoonheim MM; Geurts JJG
Brain; 2018 Sep; 141(9):2605-2618. PubMed ID: 30169585
[TBL] [Abstract][Full Text] [Related]
14. Early accurate diagnosis crucial in multiple sclerosis.
Tur C; Thompson AJ
Practitioner; 2015 Sep; 259(1785):21-7, 2-3. PubMed ID: 26591653
[TBL] [Abstract][Full Text] [Related]
15. Composite Marker of Cognitive Dysfunction and Brain Atrophy is Highly Accurate in Discriminating Between Relapsing-Remitting and Secondary Progressive Multiple Sclerosis.
Kizlaitienė R; Kaubrys G; Giedraitienė N; Ramanauskas N; Dementavičienė J
Med Sci Monit; 2017 Feb; 23():588-597. PubMed ID: 28145395
[TBL] [Abstract][Full Text] [Related]
16. Discussing the potential for progression with patients newly diagnosed with multiple sclerosis: When, how, and why?
Shosha E; Burton JM
Mult Scler Relat Disord; 2022 Dec; 68():104230. PubMed ID: 36240704
[TBL] [Abstract][Full Text] [Related]
17. Mitoxantrone in relapsing-remitting and rapidly progressive multiple sclerosis: Ten-year clinical outcomes post-treatment with mitoxantrone.
Foo EC; Russell M; Lily O; Ford HL
Mult Scler Relat Disord; 2020 Sep; 44():102330. PubMed ID: 32599468
[TBL] [Abstract][Full Text] [Related]
18. A longitudinal study of brain atrophy and cognitive disturbances in the early phase of relapsing-remitting multiple sclerosis.
Zivadinov R; Sepcic J; Nasuelli D; De Masi R; Bragadin LM; Tommasi MA; Zambito-Marsala S; Moretti R; Bratina A; Ukmar M; Pozzi-Mucelli RS; Grop A; Cazzato G; Zorzon M
J Neurol Neurosurg Psychiatry; 2001 Jun; 70(6):773-80. PubMed ID: 11385012
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic aspects of multiple sclerosis and future therapeutic options.
Jamebozorgi K; Rostami D; Pormasoumi H; Taghizadeh E; Barreto GE; Sahebkar A
Int J Neurosci; 2021 Jan; 131(1):56-64. PubMed ID: 32075477
[TBL] [Abstract][Full Text] [Related]
20. Identification and diagnosis of Secondary Progressive Multiple Sclerosis during the clinical encounter: Results from a physician survey.
Alvarez E; Nair KV; Gorritz M; Bartolome L; Maloney H; Ding Y; Golan T; Wade RL; Kumar R; Su W; Shah R; Russo P
Mult Scler Relat Disord; 2021 May; 50():102858. PubMed ID: 33799068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
